ArticleOncoimmunology2016

Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients.

Yu Sawada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.